Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : InvestRight - Short Term Trading St -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (127)	9/13/1998 1:01:00 AM
From: mike mulhearn	Read Replies (1) \| Respond to of 939

Jeff, you are correct. There are a couple companies involved with similar devices, but, I believe they are private. And I think I read somewhere that EXTI would be able to offer this device cheaper than thier competitors. There is an exti thread with a ton of info on it. Your ABMI was around .04 at one time. :>) This device does to livers what OZON does for fruits and vegies. :>) And I do recall making some good money on OZON

To: Jeffrey L. Henken who wrote (127)	9/13/1998 1:19:00 AM
From: mike mulhearn	Read Replies (1) \| Respond to of 939

Hepatix and Vitagen are the other two companies, but, I don't think they are public. Here's a letter from Exti President. Pay attention to the 3rd paragraph from the bottom. President's Letter from Annual Report: Dear Fellow Shareholder: Over the past year, Exten Industries, Inc. has done a major job of cleaning up the financial and legal problems inherited from it's prior management. In fact, most legal issues have now been put behind us and the net loss for fiscal year 1997 is about one tenth what it was the preceding year. Exten Industries formed a new subsidiary, Xenogenics Corporation, to further develop its SybiolR artificial liver technology. James Considine, MD, MBA was elected president. The company and subsidiary are now better positioned to move forward with the bio-liver device development and clinical trials. Other highlights of the year include the expansion of the Scientific Advisory Board under the direction of John Brems, MD, FACS, formerly at Scripps Clinic and Research Foundation in La Jolla, CA, and now at Loyola University in Chicago, IL. New members added in 1997 include: David Van Thiel, Director of Liver Transplantation at Loyola University; Donald Cramer, DVM, Ph.D., Director of Transplantation Biology Research at St. Vincent's Medical Center in Los Angeles; Michael Ishitani, MD, FACS of University Hospitals of Cleveland; and Daniel Salomon, MD, Director of Transplantation Research at the Scripps Clinic and Research Foundation. Initial funding has been received and clinical research activities will commence shortly. Pre-clinical as well as FDA clinical research will be conducted at Loyola University Medical Center in Chicago starting in early 1998. Patent applications have been filed under the Patent Cooperative Treaty ("PCT") in 15 countries. There is, as yet, no artificial liver device on the market. Due to the prevalence and awareness of liver disease and the scarcity of donor organs, the company believes that there is a great worldwide need for an "artificial liver". We also believe that our proposed methodology will offer cost and treatment advantages over proposed competitive devices. Strategic partnerships are being investigated and the Company is seeking an aquisition, merger, or strategic alliance with a profitable company. In summary, the Company is now positioned as a biomedical research organization with excellent technology. Our primary objective is to bring this technology to commercial viability as rapidly as possible. Thank you all for your patience and support over the past year. Your management team is dedicated to insuring that your continued support will be rewarded in the years ahead. Sincerely, W. Gerald Newmin, Chairman, CEO and President